Provisio Medical Names Physician Advisory Board to Help Guide Commercialization

May 6, 2024—Provisio Medical, Inc. announced the formation of a Physician Advisory Board composed of a multidisciplinary group of physicians who will provide input and feedback on product development decisions, outcome-focused clinical studies, and therapeutic applications of Provisio’s core sonic lumen tomography intravascular ultrasound (SLT IVUS) technology for the treatment of patients with peripheral artery disease.

The company recently announced FDA 510(k) clearance of the SLT IVUS system, which is designed to enable vessel lumen measurement and visualization simultaneously with guidewire support and delivery of radiopaque contrast agents.

The members of the Physician Advisory Board are David Deaton, MD; Zola N’Dandu, MD; Mahmood Razavi, MD; Peter Schneider, MD; and Bret Wiechmann, MD. The board members’ biographies are available on the company’s website here.

“I am thrilled to be working closely with Provisio Medical on the development of SLT IVUS technology,” commented Dr. N’Dandu in the company’s press release. “This collaboration underscores our commitment to pushing the boundaries of medical innovation and improving patient care together. I look forward to collaborating with my colleagues from all the different specialties in this endeavor.”

Dr. Deaton further noted, “Precision in endovascular techniques has a profound impact on outcomes and is sadly lacking in current practice. A platform that enables clinicians’ visibility and access to precise measurements, without disrupting conventional workflows, has the potential to transform outcomes and our ability to study and understand the therapies we employ.”

S. Eric Ryan, MD, Provisio’s Chief Executive Officer, stated in the press release, “We are honored to draw upon the expertise of such a distinguished multidisciplinary group of physicians to continue our mission of improving endovascular interventions. We will rely upon each member’s unique background, clinical area of focus and interest, as well as the dynamics of their care setting, in guiding strategic decisions for the company.”